Laden...
| No images? Click here JOINT PRESS RELEASE GLOBAL LEADERS COMMIT FURTHER SUPPORT FOR GLOBAL EQUITABLE ACCESS TO COVID-19 VACCINES AND COVAX · Leaders pledge financing, dose donations, support for country readiness and delivery and scale up of global manufacturing, to enable equitable access to COVID-19 vaccines · To improve access for lower-income economies, the United States will contribute an additional 500 million doses of Pfizer vaccine to be delivered through COVAX, beginning in 2022, and Sweden will provide an additional SEK 2.1 billion (approximately US$243 million) through 2021 and 2022 · New dose commitments from the European Union, including Italy and Spain, as well as Sweden, Denmark, and Japan mean further doses will be available to COVAX participants in 2021 and 2022 Geneva/New York/Oslo 23 September 2021 – Global leaders attending the Global COVID-19 Summit hosted by the United States have again underlined their commitment to ensuring equitable access to COVID-19 vaccines for all countries through COVAX – noting that equitable access is essential to end the acute stage of the pandemic. Building on the momentum and global solidarity generated over the past eighteen months by various commitments including at summits organised by the European Commission, the G20 under the Saudi and Italian presidencies, the United Kingdom (UK), including the G7 under the UK presidency, the United States, and the Prime Minister of Japan, yesterday’s Summit saw further pledges made to COVAX and equitable access. As the host of the Summit, the United States presented a target to vaccinate the world and as part of its commitment, pledged an additional 500 million doses of Pfizer vaccine to be delivered to low- and lower-middle-income countries through COVAX. These doses are in addition the deal for 500 million Pfizer doses facilitated by the United States, announced in June, and more than 90 million surplus doses shared through COVAX, bringing the US total doses to be provided through COVAX to nearly 1.1 billion doses. With deliveries of previously pledged doses underway, these additional doses will be made available beginning in January 2022. In addition, the US International Development Finance Corporation (DFC) will provide more than $383 million in political risk insurance to Gavi, the Vaccine Alliance (Gavi) to facilitate shipments around the world. The United States and the European Union announced a joint agenda for combatting the global pandemic, reemphasising commitments to share doses with COVAX and support critical readiness activities, and calling on other nations to do the same – particularly emphasising the importance of predictable and effective dose-sharing to maximize sustainability of the process and minimize wastage of doses. Building on previous pledges, Team Europe committed to share 500 million doses by mid-2022. Emphasising the close partnership between the African Union / AVAT and COVAX in delivering doses to African countries, South African President Cyril Ramaphosa called on higher-income countries to trade places in production queues and to support the AU and COVAX in their shared goal of increasing coverage across the African continent. In addition to the US$ 285 million Sweden has already pledged to the Gavi COVAX Advance Market Commitment (AMC), the financing mechanism which enables access to fully donor-funded doses for 92 lower-income economies, Sweden announced that a new pledge of SEK 2.1 billion (approximately US$ 243 million) in cash contributions and dose donations, will be made available to support equitable access to COVID-19 vaccines to AMC-eligible economies through 2021 and 2022. Alongside these commitments, several countries pledged additional dose donations to be made available to countries around the world, including through COVAX, with Spain pledging an additional 7.5 million doses, Italy pledging an additional 30 million doses to be made available by the end of the year, and Japan, which hosted the “One World Protected” Gavi COVAX AMC Summit in June 2021, pledging approximately 60 million doses. In addition, Denmark announced during the United Nations General Assembly this week that it would be doubling its dose donation commitment, bringing the total to 6 million doses pledged to be shared. José Manuel Barroso, Chair of the Gavi Board, said: “This Summit marks a major step forward in the global response against COVID-19 and a major step forward for multilateralism. I would like to thank President Biden and all leaders for their commitment to global access to vaccines and urge all partners and stakeholders to increase their support of COVAX, so that we can meet our objective of ending the acute phase of this pandemic as quickly as possible.” Dr Richard Hatchett, CEO of the Coalition for Epidemic Preparedness Innovations (CEPI) “Science has made huge progress in the fight to save lives, restore the global economy, and end the pandemic. Now we must redress the central moral failing of the world’s response to the pandemic, which is the lack of equitable access to the life-saving tools we have developed. This will require continued investment in R&D so we are able to deploy more vaccines, more effectively and create equity between countries of all income levels with regard to access to these life-saving vaccines.” Dr Tedros Adhanom Ghebreyesus, WHO Director-General, said: “I am grateful to President Biden and world leaders for the commitment they have shown to vaccinate the world. However, what we need to succeed is truly sustainable, ironclad support that gets delivered now – not in 6 months or 12 months time. If we are to meet the targets we have set of vaccinating 10% of the population of all countries by the end of this month, 40% by the end of 2021 and 70% by mid next-year, we need to drastically scale up access to vaccines now.” UNICEF Executive Director Henrietta Fore said: “We welcome world leaders’ renewed commitment to provide vaccine doses to low-income countries. We laud the US pledge of 500 million additional doses next year, as well as the announcements made by the European Union, Denmark, Japan, Italy and Spain, and hope to see these promises fulfilled urgently. With only 12 per cent of the pledges made earlier this year turning into actual doses, low-income countries can no longer wait. We urge dose-sharing countries to accelerate their donation plans.” Dr Seth Berkley, CEO of Gavi, said: “With the rise of variants and the current gap in equitable access to COVID-19 vaccines we must urgently vaccinate those most at risk everywhere in the world. We cannot afford further delays in getting vaccines to the most vulnerable – to do so will mean a continuation of this pandemic and its impact on all of our lives.” COVAX has recently published an updated supply forecast, which indicates that while COVAX deliveries to countries are accelerating and will continue to ramp up dramatically through the end of year, significant risks remain. As a result COVAX partners have issued an urgent call to action – for the lifting of all export restrictions, for manufacturers to deliver on their commitments to COVAX and provide transparency on delivery schedules and queues. COVAX also calls for countries who are ahead in manufacturers’ queues and have already achieved high coverage to give up their place in the queue to COVAX and the low and middle-income participants it supports, and for the expansion, acceleration and systemization of dose donations to provide greater volumes, lead times, and shelf lives, allowing countries to better prepare for rollouts. So far COVAX has delivered more than 300 million doses to 142 economies, and according to the latest forecast, a total of approximately 1.2 billion doses will be available for the lower income economies supported by the COVAX Advance Market Commitment (AMC) by the end of 2021. This is enough to protect 20% of the population, or 40% of all adults, in all 92 AMC economies with the exception of India. The key COVAX milestone of two billion doses released for delivery is now expected to be reached in the first quarter of 2022. Notes to editors About COVAX COVAX, the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator, is co-convened by the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, the Vaccine Alliance Gavi) and the World Health Organization (WHO) – working in partnership with UNICEF as key implementing partner, developed and developing country vaccine manufacturers, the World Bank, and others. It is the only global initiative that is working with governments and manufacturers to ensure COVID-19 vaccines are available worldwide to both higher-income and lower-income countries. CEPI’s role in COVAX CEPI is leading on the COVAX vaccine research and development portfolio, investing in R&D across a variety of promising candidates, with the goal to support development of three safe and effective vaccines which can be made available to countries participating in the COVAX Facility. As part of this work, CEPI has secured first right of refusal to potentially over one billion doses for the COVAX Facility to a number of candidates, and made strategic investments in vaccine manufacturing, which includes reserving capacity to manufacture doses of COVAX vaccines at a network of facilities, and securing glass vials to hold 2 billion doses of vaccine. CEPI is also investing in the ‘next generation’ of vaccine candidates, which will give the world additional options to control COVID-19 in the future. Gavi’s role in COVAX Gavi leads on procurement and delivery at scale for COVAX: designing and managing the COVAX Facility and the Gavi COVAX AMC and working with its traditional Alliance partners UNICEF and WHO, along with governments, on country readiness and delivery. As part of this role, Gavi hosts the Office of the COVAX Facility to coordinate the operation and governance of the mechanism as a whole, holds financial and legal relationships with 193 Facility participants, and manages the COVAX Facility deals portfolio: negotiating advance purchase agreements with manufacturers of promising vaccine candidates to secure doses on behalf of all COVAX Facility participants. Gavi also coordinates design, operationalisation and fundraising for the Gavi COVAX AMC, the mechanism that provides access to donor-funded doses of vaccine to 92 lower-income economies. As part of this work, Gavi provides funding and oversight for UNICEF procurement and delivery of vaccines to all AMC participants – operationalising the advance purchase agreements between Gavi and manufacturers – as well as support for partners’ and governments work on readiness and delivery. This includes tailored support to governments, UNICEF, WHO and other partners for cold chain equipment, technical assistance, syringes, vehicles, and other aspects of the vastly complex logistical operation for delivery. Gavi also co-designed, raises funds for and supports the operationalisation of the AMC’s no fault compensation mechanism as well as the COVAX Humanitarian Buffer. WHO’s role in COVAX WHO has multiple roles within COVAX: It provides normative guidance on vaccine policy, regulation, safety, R&D, allocation, and country readiness and delivery. Its Strategic Advisory Group of Experts (SAGE) on Immunization develops evidence-based immunization policy recommendations. Its Emergency Use Listing (EUL) / prequalification programmes ensure harmonized review and authorization across member states. It provides global coordination and member state support on vaccine safety monitoring. It developed the target product profiles for COVID-19 vaccines and provides R&D technical coordination. WHO leads, together with UNICEF, the Country Readiness and Delivery workstream, which provides support to countries as they prepare to receive and administer vaccines. Along with Gavi and numerous other partners working at the global, regional, and country-level, the CRD workstream provides tools, guidance, monitoring, and on the ground technical assistance for the planning and roll-out of the vaccines. Along with COVAX partners, WHO has developed a no-fault compensation scheme as part of the time-limited indemnification and liability commitments UNICEF’s role in COVAX UNICEF is leveraging its experience as the largest single vaccine buyer in the world and working with manufacturers and partners on the procurement of COVID-19 vaccine doses, as well as freight, logistics and storage. UNICEF already procures more than 2 billion doses of vaccines annually for routine immunisation and outbreak response on behalf of nearly 100 countries. In collaboration with the PAHO Revolving Fund, UNICEF is leading efforts to procure and supply doses of COVID-19 vaccines for COVAX. In addition, UNICEF, Gavi and WHO are working with governments around the clock to ensure that countries are ready to receive the vaccines, with appropriate cold chain equipment in place and health workers trained to dispense them. UNICEF is also playing a lead role in efforts to foster trust in vaccines, delivering vaccine confidence communications and tracking and addressing misinformation around the world. About ACT-Accelerator The Access to COVID-19 Tools ACT-Accelerator, is a new, ground-breaking global collaboration to accelerate the development, production, and equitable access to COVID-19 tests, treatments, and vaccines. It was set up in response to a call from G20 leaders in March and launched by the WHO, European Commission, France and The Bill & Melinda Gates Foundation in April 2020. The ACT-Accelerator is not a decision-making body or a new organisation, but works to speed up collaborative efforts among existing organisations to end the pandemic. It is a framework for collaboration that has been designed to bring key players around the table with the goal of ending the pandemic as quickly as possible through the accelerated development, equitable allocation, and scaled up delivery of tests, treatments and vaccines, thereby protecting health systems and restoring societies and economies in the near term. It draws on the experience of leading global health organisations which are tackling the world’s toughest health challenges, and who, by working together, are able to unlock new and more ambitious results against COVID-19. Its members share a commitment to ensure all people have access to all the tools needed to defeat COVID-19 and to work with unprecedented levels of partnership to achieve it. The ACT-Accelerator has four areas of work: diagnostics, therapeutics, vaccines and the health system connector. Cross-cutting all of these is the workstream on Access & Allocation. Media Contacts CEPI Press Office Meg Sharafudeen, Gavi Iryna Mazur, Gavi Evan O’Connell, Gavi Laura Shevlin, Gavi Cirũ Kariũki, Gavi WHO Press Office Kurtis Cooper, UNICEF New York Anne Sophie Bonefeld, UNICEF Copenhagen You are receiving this NO-REPLY email because you are included on a WHO mail list.
|
Laden...
Laden...
© 2024
